Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05038735 |
|---|---|
| Brief Title: | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5) |
| First Submitted : | September 1, 2021 |
| First Submitted that Met QC Criteria : | September 1, 2021 |
| First Posted : | September 9, 2021 |
| Last Update Submitted that Met QC Criteria : | May 4, 2024 |
| Last Update Posted : | May 7, 2024 |